Vera Therapeutics Q2 net loss $14.9M, cash $131.9M; Phase 2b atacicept enrollment complete

Vera Therapeutics, Inc.

2022-Q2 EPS reported -$1.24

Net loss of $14.9M ($0.55 per share) vs $3.4M ($0.33) in Q2 2021.
Cash, equivalents, and securities $131.9M at June 30, 2022; plus $45M credit facility.
Completed enrollment in Phase 2b ORIGIN trial of atacicept for IgA nephropathy; topline data expected early Q1 2023.
Appointed Michael M. Morrissey, Ph.D., CEO of Exelixis, as Chairman of the board.
Plan to initiate Phase 3 atacicept trial in lupus nephritis in H2 2022 and Phase 2b/3 MAU868 in BKV in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.